Author:
Lau Sally C.M.,Perdrizet Kirstin,Fung Andrea S.,Mata Danilo Giffoni M.M.,Weiss Jessica,Holzapfel Nick,Liu Geoffrey,Bradbury Penelope A.,Shepherd Frances A.,Sacher Adrian G.,Feilotter Harriet,Sheffield Brandon,Hwang David,Tsao Ming Sound,Cheng Susanna,Cheema Parneet,Leighl Natasha B.
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference27 articles.
1. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non–small cell lung carcinoma with poor prognosis;Tong;Clin Cancer Res,2016
2. Characterization of 298 patients with lung cancer harboring MET Exon 14 skipping alterations;Schrock;J Thorac Oncol,2016
3. MET exon 14 skipping mutations in non–small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations;Socinski;JCO Precis Oncol,2021
4. Characteristics and clinical outcomes of non-small cell lung cancer patients in Korea with MET exon 14 skipping;Hur;In Vivo,2020
5. Targeting MET in lung cancer: will expectations finally be MET?;Drilon;J Thorac Oncol,2017